Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

Key Points Ixazomib, cyclophosphamide, and dexamethasone combination achieved hematologic response in 63% of newly diagnosed AL amyloidosis patients. The regimen is characterized with a favorable adverse event profile and should be explored in other combinations.